ArticleJournal of hepatocellular carcinoma2026
Angiogenic Prognostic Signature for Stratification in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. Angiogenesis drives HCC progression, but reliable biomarkers remain limited. Methods: We analyzed angiogenesis‑related genes (ARGs) using TCGA data, constructed a prognostic signature via LASSO‑Cox regression, and validated it in ICGC and real‑world HCC cohorts. Functional experiments (in vitro and in vivo) were performed for Secretory phosphoprotein 1 (SPP1). Single‑cell RNA‑seq data mapped cellular sources of signature genes. Drug sensitivity (GDSC2) and sorafenib‑treated GEO data assessed therapy response. Results: A four-gene ARG signature (APOH, SLCO2A1, SPP1, VTN) stratified HCC patients into high- and low-risk groups with distinct survival, validated in external cohorts. The high‑risk group showed enriched immune checkpoint expression and stromal activity. Single‑cell analysis revealed SPP1 mainly from macrophages and hepatocytes; VTN, APOH, and SLCO2A1 from monocyte/macrophage subsets. SPP1 knockdown suppressed endothelial angiogenesis in vitro and in vivo. High‑risk patients exhibited reduced sorafenib sensitivity (higher IC50), and sorafenib treatment downregulated APOH, SPP1, and VTN but not SLCO2A1. Conclusion: We established a robust ARG‑based prognostic signature for HCC that improves risk stratification and highlights links between angiogenesis, immune microenvironment, and drug response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.